Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590097 | 1.00 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12087530 | 1.00 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL16587646 | 0.92 | TK1 (0.39) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19884483 | 0.91 | TK1 (0.38) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13515629 | 0.91 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13513432 | 0.91 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12015175 | 0.89 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19840296 | 0.89 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12646692 | 0.89 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12590107 | 0.89 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | TK1 86/4885ALDH1A1 3907/4885LMNA 1087/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | TK1 192/4885ALDH1A1 2161/4885LMNA 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.